MMSI

AI Memo

Merit Medical

As of 2026-09-12/Confidence high/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-12 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

6‑12m

Key catalyst

Execution against raised full-year 2026 guidance • 2026-12-31

Base target: $94 / p=50% prob

Biggest risk

Year-to-date operating cash flow fell 11% and free cash flow fell 14%; Q2 Procedural Solutions constant-currency revenue declined 12%, while Renal Therapies declined 2%. The outlook also excludes adverse effects from trade-policy actions implemented after July 30, leaving execution and policy risk. [#SEC-8K-2026-07-30]

Invalidation

Break below $72 or thesis failure.

What would change my mind?

Q2 revenue rose 10% to $418.8 million, organic constant-currency growth reached 9%, and non-GAAP operating margin expanded 140 basis points to 22.6%. Management raised full-year revenue and non-GAAP EPS guidance, supporting a moderate upside case if therapeutic-product strength persists. [#SEC-8K-2026-07-30]

Research note

Recommendation

—

Confidence

high

As of

2026-09-12

Base target

$94

p=50%

Bull target

$105

p=30%

Bear target

$72

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Therapeutic portfolio growth durability
Operating leadership and longer-term strategic-plan execution
Q2 revenue rose 10% to $418.8 million, organic constant-currency growth reached 9%, and non-GAAP operating margin expanded 140 basis points to 22.6%.

BearKey bullets

Cash conversion weakened despite earnings growth: year-to-date operating cash flow declined 11% and free cash flow declined 14%.
[#SEC-8K-2026-07-30]
Growth is uneven across the portfolio, with Q2 constant-currency declines in Procedural Solutions and Renal Therapies.

WatchKey bullets

Execution against raised full-year 2026 guidance

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $94 (p=50%)

Target spread vs base: +12% / -23%

Scenario probabilities

Bull Target: $105 (p=30%)Base Target: $94 (p=50%)Bear Target: $72 (p=20%)

Commentary

Primary-source tone is constructive following an expectation-beating Q2 and raised 2026 guidance, but recent news coverage is sparse and no sufficient social, options, short-interest, employee, or post-print analyst-revision data was supplied. The numerical sentiment fields without packet coverage are unavailable proxies rather than observed signals and should not influence the thesis. The $86.36 anchor is below the COO's August 24 sale price, but no causal inference should be drawn from that comparison.

As of 2026-09-12 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Therapeutic portfolio growth durability
Operating leadership and longer-term strategic-plan execution

Scenarios

Bull Target (Scenario probability)

$105 / p=30% prob

Base Target (Scenario probability)

$94 / p=50% prob

Bear Target (Scenario probability)

$72 / p=20% prob

Analysis 2026-09-12 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Execution against raised full-year 2026 guidance
Merit raised 2026 revenue guidance to $1.631-$1.643 billion and non-GAAP EPS guidance to $4.25-$4.35 after Q2 results exceeded its expectations. Delivery through year-end would support estimate confidence; the catalyst is partly reflected in the shares. [#SEC-8K-2026-07-30]
Prob 65.00% • Move 10.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Therapeutic portfolio growth durability
2026-12-31
Q2 therapeutic revenue grew 14% in constant currency, led by Cardiac Therapies and Endoscopy growth of 22% and 29%, respectively. Confirmation that these gains persist while Foundational Procedural Solutions and Renal Therapies stabilize would improve the quality of the growth outlook. [#SEC-8K-2026-07-30]
Prob 60% • Move 8% • Priced-in 50%

Long-term Catalysts

Months to a year

Operating leadership and longer-term strategic-plan execution
2027-06-30
Sheri Lewis became Executive Vice President of Global Operations effective August 31, while management is developing a longer-term plan aimed at sustainable growth and enhanced profitability. Evidence of operational improvements or credible post-2026 targets could broaden the thesis, but neither outcome is quantified yet. [#8-K-2026-08-20] [#SEC-8K-2026-07-30]
Prob 45% • Move 7% • Priced-in 20%

Risks

Cash conversion weakened despite earnings growth: year-to-date operating cash flow declined 11% and free cash flow declined 14%. [#SEC-8K-2026-07-30]
Growth is uneven across the portfolio, with Q2 constant-currency declines in Procedural Solutions and Renal Therapies. [#SEC-8K-2026-07-30]
The COO reported two August open-market sales totaling 28,949 shares; transaction motives are not disclosed and the filings do not establish an operating signal. [#SEC-FORM4-2026-08-05] [#SEC-FORM4-2026-08-25]
The supplied peer set is loose and analyst-target coverage is unspecified, reducing confidence in relative valuation and consensus-based upside.
Updated guidance excludes potential effects from subsequent trade-policy actions, acquisitions, non-recurring transactions, and other factors outside current expectations. [#SEC-8K-2026-07-30]

Peers

Symbol	Summary
BSX	Relevant cardiovascular-device comparator, but Boston Scientific's much larger scale and different portfolio mix limit direct valuation comparability.
ABT	Useful diversified medtech demand and margin reference, though Abbott's diagnostics, nutrition, and pharmaceutical exposure make it a broad rather than direct peer.
EW	Relevant procedure-driven cardiovascular comparator, but its structural-heart concentration differs materially from Merit's diversified interventional portfolio.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-12

Loading AI feed…

Symbol

Summary

BSX

Relevant cardiovascular-device comparator, but Boston Scientific's much larger scale and different portfolio mix limit direct valuation comparability.

ABT

Useful diversified medtech demand and margin reference, though Abbott's diagnostics, nutrition, and pharmaceutical exposure make it a broad rather than direct peer.

Relevant procedure-driven cardiovascular comparator, but its structural-heart concentration differs materially from Merit's diversified interventional portfolio.